Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.6K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.6K
Inhaled Medications01:23

Inhaled Medications

818
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
818
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

831
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
831
Pulmonary Ventilation: Inhalation01:24

Pulmonary Ventilation: Inhalation

8.4K
Pulmonary ventilation is a vital process that ensures the exchange of oxygen and carbon dioxide in the lungs. It refers to the movement of air into and out of the lungs, enabling the body to obtain oxygen and remove waste carbon dioxide. In this article, we will explore the intricacies of pulmonary ventilation, including its underlying principles, mechanisms, and the interplay of pressures within the respiratory system.
Boyle's law becomes particularly pertinent when examining respiratory...
8.4K
Inhalational Anesthetics: Overview01:20

Inhalational Anesthetics: Overview

1.2K
Inhalation anesthetics are drugs that induce general anesthesia upon inhalation. They work by increasing the sensitivity of GABAA receptors or inhibiting NMDA receptors, leading to a decrease in central nervous system activity. The depth of anesthesia can be rapidly adjusted by changing the concentration of the inhaled gas. Some common examples of inhalational anesthetics include volatile liquids like isoflurane, desflurane, sevoflurane and gases like xenon and nitrous oxide. Isoflurane, a...
1.2K
Lung Capacity01:47

Lung Capacity

56.4K
The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Paediatric bronchiectasis phenotypes and their association with clinical outcomes: development and validation in two prospective clinical cohorts.

Thorax·2026
Same author

Neutrophil-related gene expression profile is associated with future paediatric bronchiectasis exacerbations.

Journal of molecular medicine (Berlin, Germany)·2026
Same author

Improving asthma control assessment and outcomes in children with asthma using an artificial intelligence digital tool: a prospective multicentre cohort study.

ERJ open research·2026
Same author

Development of a paediatric severity score to predict outcomes of radiographic-confirmed community-acquired pneumonia in hospitalised children in Sabah, Malaysia.

Archives of disease in childhood·2026
Same author

Short and long-term effects of a play-based therapeutic exercise programme in children with non-cystic fibrosis bronchiectasis: A randomised controlled trial.

Journal of science and medicine in sport·2026
Same author

Improving the management and outcomes of preschool wheeze: protocol of a prospective multicentre cohort study.

BMJ open respiratory research·2026

Related Experiment Video

Updated: Feb 10, 2026

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

1.9K

Inhaled corticosteroids for bronchiectasis.

Nitin Kapur1, Helen L Petsky, Scott Bell

  • 1Department of Respiratory and Sleep Medicine, Children's Health Queensland, Lady Cilento Children's Hospital, Brisbane, Queensland, Australia.

The Cochrane Database of Systematic Reviews
|May 17, 2018
PubMed
Summary
This summary is machine-generated.

This review found insufficient evidence to support the routine use of inhaled corticosteroids (ICS) for stable bronchiectasis in adults. More research is needed to determine their efficacy and safety in children and during acute exacerbations.

More Related Videos

Whole-Body Nanoparticle Aerosol Inhalation Exposures
10:11

Whole-Body Nanoparticle Aerosol Inhalation Exposures

Published on: May 7, 2013

16.3K
Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System
06:07

Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System

Published on: October 22, 2020

7.7K

Related Experiment Videos

Last Updated: Feb 10, 2026

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

1.9K
Whole-Body Nanoparticle Aerosol Inhalation Exposures
10:11

Whole-Body Nanoparticle Aerosol Inhalation Exposures

Published on: May 7, 2013

16.3K
Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System
06:07

Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System

Published on: October 22, 2020

7.7K

Area of Science:

  • Pulmonology
  • Clinical Medicine
  • Pharmacology

Background:

  • Bronchiectasis is a chronic lung disease characterized by irreversible airway dilation, inflammation, and infection.
  • It affects both adults and children globally, necessitating effective management strategies.
  • Current medical management focuses on symptom control, reducing exacerbations, and preventing disease progression.

Purpose of the Study:

  • To evaluate the efficacy and safety of inhaled corticosteroids (ICS) in adults and children with stable bronchiectasis.
  • To determine if ICS reduce the frequency and severity of acute respiratory exacerbations.
  • To assess the impact of ICS on long-term pulmonary function decline.

Main Methods:

  • A systematic review of randomized controlled trials (RCTs) comparing ICS with placebo or no medication.
  • Searches included Cochrane Register, Cochrane Airways Group Register, MEDLINE, and Embase up to June 2017.
  • Included studies involved adults and children with bronchiectasis, excluding cystic fibrosis.

Main Results:

  • Seven studies with 380 adults were included; 348 completed the trials.
  • Short-term ICS use (≤6 months) showed no significant difference in FEV1, FVC, exacerbation frequency, or HRQoL compared to no ICS.
  • Long-term ICS use (>6 months) also showed no significant effect on lung function or other clinical outcomes. Evidence quality was low.

Conclusions:

  • Insufficient evidence exists to support the routine use of ICS in adults with stable bronchiectasis.
  • No conclusions can be drawn regarding ICS use in adults during acute exacerbations or in children due to a lack of studies.